The Patent Office

INVESTOR IN PEOPLE

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed P. Mahoney

Dated 13 November 2003

Patents Form 1/77

Patents Act 1977
(Rule 16)

The Patent Office

1/77

03JUN03 E811811-1 D01030
P01/7700 0.00-0312607.5

THE PATENT OFFICE
J
-2 JUN 2003
LONDON

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office
Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference — MG/PMS/P33159P1

2. Patent application number — 0 2 JUN 2003 — 0312607.5
(The Patent Office will fill in his part)

3. Full name, address and postcode of the or of each applicant *(underline all surnames)*

Glaxo Group Limited
Glaxo Wellcome House, Berkeley Avenue,
Greenford, Middlesex UB6 0NN, Great Britain

Patents ADP number *(if you know it)*

If the applicant is a corporate body, give the country/state of its incorporation — United Kingdom — 4735870003

4. Title of the invention — Novel Compounds

5. Name of your agent *(if you have one)*

Corporate Intellectual Property

"Address for service" in the United Kingdom to which all correspondence should be sent *(including the postcode)*

GlaxoSmithKline
Corporate Intellectual Property (CN9 25.1)
980 Great West Road
BRENTFORD
Middlesex TW8 9GS

Patents ADP number *(if you know it)* — 7960982005

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or each of these earlier applications and *(if you know it)* the or each application number

Country	Priority application number *(if you know it)*	Date of filing *(day / month / year)*

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application	Date of filing *(day / month / year)*

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? *(Answer yes if:*

a) any applicant named in part 3 is not an inventor, or
b) there is an inventor who is named as an applicant, or
c) any named applicant is a corporate body
See note (d)

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form	0
Description	39
Claim(s)	2
Abstract	0
Drawings	0

10. If you are also filing any of the following, state how many against each item.

Priority Documents	
Translations of priority documents	
Statement of inventorship and right to grant of a patent *(Patents Form 7/77)*	
Request for preliminary examination and search *(Patents Form 9/77)*	
Request for substantive examination *(Patents Form 10/77)*	
Any other documents *(please specify)*	

11. We request the grant of a patent on the basis of this application

Signature M Gibson Date 2-Jun-03

12. Name and daytime telephone number of person to contact in the United Kingdom

M Gibson 01279 644841

Warning

After an application for a Patent has beeen filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed tf it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission unless an application has been filed at least six weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505
b) Write your answers in capital letters using black ink or you may type them.
c) If there is not enough space for all relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
f) For details of the fee and ways to pay please contact the Patent Office.

Novel Compounds

The present invention relates to novel benzazepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.

JP 2001226269 and WO 00/23437 (Takeda Chem Ind Ltd) describe a series of benzazepine derivatives which are claimed to be useful in the treatment of obesity. DE 2207430, US 4,210,749 and FR 2171879 (Pennwalt Corp) and GB 1268243 (Wallace and Tiernan Inc) all describe a series of benzazepine derivatives which are claimed as being antagonists for narcotics (such as morphine or codeine) and also anti-histamines and anticholinergic agents. WO 02/14513 (Takeda Chem Ind Ltd) describe a series of benzazepine derivatives with GPR12 activity which are claimed to be useful in the treatment of attention deficit disorder, narcolepsy or anxiety. WO 02/02530 (Takeda Chem Ind Ltd) describe a series of benzazepine derivatives as GPR14 antagonists which are claimed to be useful in the treatment of hypertension, atherosclerosis and cardiac infarction. WO 01/03680 (Isis Innovation Ltd) describe a series of benzazepine derivatives which are claimed as effective agents in the preparation of cells for transplantation in addition to the inhibition of diseases such as diabetes. WO 00/21951 (SmithKline Beecham plc) discloses a series of tetrahydrobenzazepine derivatives as modulators of dopamine D3 receptors which are claimed to be useful as antipsychotic agents.

The histamine H3 receptor is predominantly expressed in the mammalian central nervous system (CNS), with minimal expression in peripheral tissues except on some sympathetic nerves (Leurs *et al.*, (1998), Trends Pharmacol. Sci. **19**, 177-183). Activation of H3 receptors by selective agonists or histamine results in the inhibition of neurotransmitter release from a variety of different nerve populations, including histaminergic and cholinergic neurons (Schlicker *et al.*, (1994), Fundam. Clin. Pharmacol. **8**, 128-137). Additionally, *in vitro* and *in vivo* studies have shown that H3 antagonists can facilitate neurotransmitter release in brain areas such as the cerebral cortex and hippocampus, relevant to cognition (Onodera *et al.*, (1998), In: The Histamine H3 receptor, ed Leurs and Timmerman, pp255-267, Elsevier Science B.V.). Moreover, a number of reports in the literature have demonstrated the cognitive enhancing properties of H3 antagonists (e.g. thioperamide, clobenpropit, ciproxifan and GT-2331) in rodent models including the five choice task, object recognition, elevated plus maze, acquisition of novel task and passive avoidance (Giovanni *et al.*, (1999), Behav. Brain Res. **104**, 147-155). These data suggest that novel H3 antagonists such as the current series could be useful for the treatment of cognitive impairments in diseases such as Alzheimer's disease and related neurodegenerative disorders.

The present invention provides, in a first aspect, a compound of formula (I) or a pharmaceutically acceptable salt thereof:



(I)

wherein:

R^1 represents -C_{3-7} cycloalkyl optionally substituted by C_{1-3} alkyl;

R^2 represents hydrogen, -C_{1-6} alkyl, -X-C_{3-8} cycloalkyl, -X-aryl, -X-heterocyclyl, -X-heteroaryl, -X-C_{3-8} cycloalkyl-Y-C_{3-8} cycloalkyl, -X-C_{3-8} cycloalkyl-Y-aryl, -X-C_{3-8} cycloalkyl-Y-heteroaryl, -X-C_{3-8} cycloalkyl-Y-heterocyclyl, -X-aryl-Y-C_{3-8} cycloalkyl, -X-aryl-Y-aryl, -X-aryl-Y-heteroaryl, -X-aryl-Y-heterocyclyl, -X-heteroaryl-Y-C_{3-8} cycloalkyl, -X-heteroaryl-Y-aryl, -X-heteroaryl-Y-heteroaryl, -X-heteroaryl-Y-heterocyclyl, -X-heterocyclyl-Y-C_{3-8} cycloalkyl, -X-heterocyclyl-Y-aryl, -X-heterocyclyl-Y-heteroaryl, -X-heterocyclyl-Y-heterocyclyl;

X represents a bond or C_{1-6} alkyl;

Y represents a bond, C_{1-6} alkyl, CO, COC_{2-6} alkenyl, O or SO_2;

R^3 represents halogen, C_{1-6} alkyl, C_{1-6} alkoxy, cyano, amino or trifluoromethyl;

n is 0, 1 or 2;

wherein said C_{1-6} alkyl, C_{3-8} cycloalkyl, aryl, heteroaryl and heterocyclyl groups of R^2 may be optionally substituted by one or more substituents (eg. 1, 2 or 3) which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, oxo, trifluoromethyl, trifluoromethoxy, fluoromethoxy, difluoromethoxy, C_{1-6} alkyl, pentafluoroethyl, C_{1-6} alkoxy, arylC_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} alkoxyC_{1-6} alkyl, C_{3-7} cycloalkylC_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkoxycarbonyl, C_{1-6} alkylsulfonyl, C_{1-6} alkylsulfinyl, C_{1-6} alkylsulfonyloxy, C_{1-6} alkylsulfonylC_{1-6} alkyl, sulfonyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC_{1-6} alkyl, aryloxy, C_{1-6} alkylsulfonamido, C_{1-6} alkylamino, C_{1-6} alkylamido, -R^4, -CO_2R^4, -COR^4, C_{1-6} alkylsulfonamidoC_{1-6} alkyl, C_{1-6} alkylamidoC_{1-6} alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC_{1-6} alkyl, arylcarboxamidoC_{1-6} alkyl, aroyl, aroylC_{1-6} alkyl, arylC_{1-6} alkanoyl, or a group -NR^5R^6, –C_{1-6} alkyl-NR^5R^6, –C_{3-8} cycloalkyl-NR^5R^6, -$CONR^5R^6$, -$NCOR^5R^6$, -$NSO_2R^5R^6$, -$OCONR^5R^6$, -$NCO_2R^5R^6$, -$NCONR^5R^6$ or -$SO_2NR^5R^6$ (wherein R^4, R^5 and R^6 independently represent hydrogen, C_{1-6} alkyl, -C_{3-8} cycloalkyl, -C_{1-6} alkyl-C_{3-8} cycloalkyl, aryl, heterocyclyl or heteroaryl or -NR^5R^6 may represent a heterocyclyl group, wherein said R^4, R^5 and R^6 groups may be optionally substituted by one or more substituents (eg. 1, 2 or 3) which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, cyano, amino, oxo or trifluoromethyl);

or solvates thereof.

Alkyl groups, whether alone or as part of another group, may be straight chain or branched and the groups alkoxy and alkanoyl shall be interpreted similarly. Alkyl moieties are more preferably C_{1-4} alkyl, eg. methyl or ethyl. The term 'halogen' is used

herein to describe, unless otherwise stated, a group selected from fluorine, chlorine, bromine or iodine.

The term "aryl" includes phenyl and naphthyl.

The term "heterocyclyl" is intended to mean a 4-7 membered monocyclic saturated or partially unsaturated aliphatic ring or a 4-7 membered saturated or partially unsaturated aliphatic ring fused to a benzene ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen or sulphur. Suitable examples of such monocyclic rings include pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydrofuranyl, tetrahydropyranyl, diazepanyl and azepanyl. Suitable examples of benzofused heterocyclic rings include indolinyl, isoindolinyl, benzodioxolyl, dihydroisoindole, dihydrobenzofuranyl and dihydroisoquinolinyl.

The term "heteroaryl" is intended to mean a 5-7 membered monocyclic aromatic or a fused 8-11 membered bicyclic aromatic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur. Suitable examples of such monocyclic aromatic rings include thienyl, furyl, pyrrolyl, triazolyl, imidazolyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyrazolyl, pyrimidyl, pyridazinyl, pyrazinyl, pyridyl and tetrahydropyranyl. Suitable examples of such fused aromatic rings include benzofused aromatic rings such as quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, cinnolinyl, naphthyridinyl, indolyl, indazolyl, pyrrolopyridinyl, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzoxadiazolyl, benzothiadiazolyl and the like.

Preferably, R^1 represents unsubstituted -C_{3-7} cycloalkyl (eg. cyclobutyl, cyclopentyl or cyclohexyl), most preferably cyclobutyl or cyclopentyl, especially cyclobutyl.

Preferably, R^2 represents

hydrogen;

-C_{1-6} alkyl (eg. CH_2) optionally substituted by a -$CONR^5R^6$ group;

–X-aryl (eg. –X-phenyl) optionally substituted by one or two halogen (eg. fluorine), C_{1-6} alkoxy (eg. methoxy), COOH, -$CONR^5R^6$, -$SO_2NR^5R^6$, -COOMe or cyano groups;

-X-aryl-Y-heterocyclyl (eg. –X-phenyl-Y-piperazinyl, -X-phenyl-Y-pyrrolidinyl or -X-phenyl-Y-morpholinyl) optionally substituted by an R^4 group;

-X-heteroaryl (eg. –X-pyridinyl, -X-pyrazinyl, -X-pyrimidinyl or –X-quinolinyl) optionally substituted by one or two halogen (eg. bromine), C_{1-6} alkyl (eg. methyl), cyano, -COOMe, -$CONR^5R^6$ or oxo groups;

-X-heteroaryl-Y-heterocyclyl (eg. –X-pyridinyl-Y-morpholinyl, –X-pyridinyl-Y-pyrrolidinyl, –X-pyridinyl-Y-piperidinyl, –X-pyridinyl-Y-thiomorpholinyl, -X-pyrazinyl-Y-morpholinyl, -X-pyrazinyl-Y-piperidinyl or –X-pyrazinyl-Y-pyrrolidinyl) optionally substituted by one or two oxo groups;

-X-heterocyclyl (eg. –X-piperidinyl or –X-pyrrolidinyl) optionally substituted by an $-SO_2Me$, $-COR^4$ or $-COR^5R^6$ group;

-X-heterocyclyl-Y-aryl (eg. –X-piperidinyl-Y-phenyl or –X-pyrrolidinyl-Y-phenyl) optionally substituted by a cyano, $-SO_2Me$, R^4 or $-CONR^5R^6$ group;

-X-heterocyclyl-Y-heterocyclyl (eg. –X-piperidinyl-Y-tetrahydropyranyl, –X-pyrrolidinyl-Y-tetrahydropyranyl, -X-piperidinyl-Y-dihydrobenzofuranyl, -X-pyrrolidinyl-Y-morpholinyl, -X-piperidinyl-Y-morpholinyl, -X-piperidinyl-Y-thiomorpholinyl, -X-piperidinyl-Y-dihydroisoindole or -X-piperidinyl-Y-piperazinyl) optionally substituted by one or two oxo or R^4 groups;

-X-heterocyclyl-Y-C_{3-8} cycloalkyl (eg. –X-piperidinyl-Y-cyclohexyl, -X-piperidinyl-Y-cyclopropyl, -X-piperidinyl-Y-cyclobutyl or –X-piperidinyl-Y-cyclopentyl); or

-X-heterocyclyl-Y-heteroaryl (eg. –X-piperidinyl-Y-isoquinolinyl, -X-piperidinyl-Y-quinolinyl, -X-piperidinyl-Y-isoxazolyl, -X-piperidinyl-Y-benzothiazol, -X-piperidinyl-Y-thiophenyl, -X-piperidinyl-Y-furanyl, –X-piperidinyl-Y-pyrazinyl, –X-piperidinyl-Y-pyridyl) optionally substituted by one or two C_{1-6} alkyl (eg. methyl) or oxo groups.

Preferably, X represents a bond or $-CH_2-$, most preferably X represents a bond.

Preferably, Y represents CO, SO_2 or COC_{2-6} alkenyl (eg. -CO-CH=CH-), most preferably Y represents CO.

More preferably, R^2 represents

–X-aryl (eg. phenyl) optionally substituted by a $CONR^5R^6$ group;

-X-aryl-Y-heterocyclyl (eg. –X-phenyl-Y-morpholinyl or –X-phenyl-Y-pyrrolidinyl);

-X-heteroaryl (eg. pyrazinyl or pyridinyl) optionally substituted by a $CONR^5R^6$ group;

-X-heteroaryl-Y-heterocyclyl (eg. –X-pyridinyl-Y-morpholinyl, –X-pyridinyl-Y-pyrrolidinyl, –X-pyridinyl-Y-piperidinyl, –X-pyridinyl-Y-thiomorpholinyl, -X-pyrazinyl-Y-morpholinyl, -X-pyrazinyl-Y-piperidinyl or -X-pyrazinyl-Y-pyrrolidinyl) optionally substituted by one or two oxo groups;

-X-heterocyclyl-Y-heterocyclyl (eg. –X-piperidinyl-Y-tetrahydropyranyl, –X-piperidinyl-Y-morpholinyl or –X-pyrrolidinyl-Y-morpholinyl).

Most preferably, R^2 represents

-X-heterocyclyl-Y-heterocyclyl (eg. –piperidinyl-CO-morpholinyl); or

-X-heteroaryl optionally substituted by a $CONR^5R^6$ group (eg. -pyridinyl optionally substituted by CONHMe).

Preferably, R^4 represents C_{1-6} alkyl (eg. ethyl or t-butyl), aryl (eg. phenyl) or heteroaryl (eg. pyridinyl or pyrazinyl) optionally substituted by a halogen (eg. fluorine) or C_{1-6} alkoxy (eg. methoxy) group.

Preferably, R^5 and R^6 independently represent hydrogen, C_{1-6} alkyl (eg. methyl, ethyl or isopropyl), -C_{3-8} cycloalkyl (eg. cyclobutyl or cyclopentyl), -C_{1-6} alkyl-C_{3-8} cycloalkyl (eg. –CH_2-cyclopropyl) or aryl (eg. phenyl) optionally substituted by a halogen (eg. fluorine), cyano or C_{1-6} alkoxy (eg. methoxy) group or –NR^5R^6 represents a heterocyclic group (eg. pyrrolidinyl).

More preferably, R^5 and R^6 independently represent hydrogen, C_{1-6} alkyl (eg. methyl or ethyl), -C_{3-8} cycloalkyl (eg. cyclobutyl or cyclopentyl) or -C_{1-6} alkyl-C_{3-8} cycloalkyl (eg. –CH_2-cyclopropyl).

Preferably, n represents 0.

Preferred compounds according to the invention include examples E1-E139 as shown below, or a pharmaceutically acceptable salt thereof.

Compounds of formula (I) may form acid addition salts with acids, such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, sulphate, citric, lactic, mandelic, tartaric and methanesulphonic. Salts, solvates and hydrates of compounds of formula (I) therefore form an aspect of the invention.

Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of these compounds and the mixtures thereof including racemates. Tautomers also form an aspect of the invention.

The present invention also provides a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises:

(a) reacting a compound of formula (II)



(II)

wherein R^1, R^3 and n are as defined above, with a compound of formula $R^{2'}$-L^1, wherein $R^{2'}$ is as defined above for R^2 or a group convertible thereto and L^1 represents a suitable leaving group such as a halogen atom (eg. bromine or iodine) or an optionally activated hydroxyl group;

(b) reacting a compound of formula (III)



(III)

wherein R^2, R^3 and n are as defined above, with a compound of formula $R^{1'}$-L^2, wherein $R^{1'}$ is as defined above for R^1 or a group convertible thereto and L^2 represents a suitable leaving group such as a halogen atom (eg. bromine, iodine or tosylate); or

(c) reacting a compound of formula (III) as defined above, with a ketone of formula $R^{1'}$=O, wherein $R^{1'}$ is as defined above for R^1 or a group convertible thereto; or

(d) deprotecting a compound of formula (I) which is protected; and

(e) interconversion to other compounds of formula (I).

When the leaving group L^1 is attached to a sp^3 hybridised carbon, for example, $R^{2'}$-L^1 is an alkyl halide, process (a) typically comprises the use of a suitable base, such as potassium carbonate in an appropriate solvent such as 2-butanone optionally in the presence of a transfer reagent such as potassium iodide at an appropriate temperature such as reflux.

When the leaving group L^1 is attached to a sp^2 hybridised carbon, for example, $R^{2'}$-L^1 is an aryl halide, process (a) typically comprises the use of a copper(I) salt, such as copper (I) iodide, in the presence of a base such as sodium hydride, in an appropriate solvent such as pyridine, at an appropriate temperature such as reflux.

When L^1 is a an optionally activated hydroxyl group attached to a sp^3 hybridised carbon, for example, $R^{2'}$-L^1 is an alcohol, process (a) typically comprises the use of a phosphine such as triphenylphosphine in a suitable solvent such as tetrahydrofuran, followed by addition of an azadicarboxylate such as diethylazaodicarboxylate at a suitable temperature such as room temperature.

Process (b) typically comprises the use of a suitable base, such as potassium carbonate in an appropriate solvent such as 2-butanone optionally in the presence of a transfer reagent such as potassium iodide at an appropriate temperature such as reflux.

Process (c) typically comprises the use of reductive conditions (such as treatment with a borohydride eg. sodium triacetoxyborohydride), optionally in the presence of an acid, such as acetic acid, in an appropriate solvent such as dichloromethane at a suitable temperature such as room temperature.

In process (d), examples of protecting groups and the means for their removal can be found in T. W. Greene 'Protective Groups in Organic Synthesis' (J. Wiley and Sons, 1991). Suitable amine protecting groups include sulphonyl (e.g. tosyl), acyl (e.g. acetyl, 2',2',2'-trichloroethoxycarbonyl, benzyloxycarbonyl or t-butoxycarbonyl) and arylalkyl (e.g. benzyl), which may be removed by hydrolysis (e.g. using an acid such as hydrochloric acid in dioxan or trifluoroacetic acid in dichloromethane) or reductively (e.g. hydrogenolysis of a benzyl group or reductive removal of a 2',2',2'-trichloroethoxycarbonyl group using zinc in acetic acid) as appropriate. Other suitable amine protecting groups include trifluoroacetyl (-$COCF_3$) which may be removed by base catalysed hydrolysis or a solid phase resin bound benzyl group, such as a Merrifield resin bound 2,6-dimethoxybenzyl group (Ellman linker), which may be removed by acid catalysed hydrolysis, for example with trifluoroacetic acid.

Process (e) may be performed using conventional interconversion procedures such as epimerisation, oxidation, reduction, alkylation, nucleophilic or electrophilic aromatic substitution, ester hydrolysis or amide bond formation.

Compounds of formula (II) and (III) may be prepared in accordance with the following scheme



wherein R^1, R^2, $R^{2'}$, R^3, n and L^1 are as defined above and P^1 represents a suitable protecting group such as Boc.

Step (i) typically comprises a deprotection reaction, for example, when P^1 represents Boc the deprotection reaction comprises reaction of a compound of formula (IV) with an acid, for example hydrochloric acid in dioxan or trifluoroacetic acid in dichloromethane.

Step (ii) may be performed under reducing conditions in an analogous manner to that described for process (b).

Step (iii) may be performed in an analogous manner to that described for process (a).

Step (iv) typically comprises a deprotection reaction to provide a compound of formula (III) and can be performed as described in step (i).

Compounds of formula (IV) may be prepared in an analogous manner to those described in Description 3 of WO 02/40471.

Compounds of formula (I) and their pharmaceutically acceptable salts have affinity for the histamine H3 receptor and are believed to be of potential use in the treatment of neurological diseases including Alzheimer's disease, dementia, age-related memory dysfunction, mild cognitive impairment, cognitive deficit, epilepsy, neuropathic pain, inflammatory pain, Parkinson's disease, multiple sclerosis, stroke and sleep disorders including narcolepsy; psychiatric disorders including schizophrenia (particularly cognitive deficit of schizophrenia), attention deficit hypereactivity disorder, depression and addiction; and other diseases including obesity, asthma, allergic rhinitis, nasal congestion, chronic obstructive pulmonary disease and gastro-intestinal disorders.

Thus the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use as a therapeutic substance in the treatment or prophylaxis of the above disorders, in particular neurodegenerative disorders including Alzheimer's disease.

The invention further provides a method of treatment or prophylaxis of the above disorders, in mammals including humans, which comprises administering to the sufferer a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

In another aspect, the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of the above disorders.

When used in therapy, the compounds of formula (I) are usually formulated in a standard pharmaceutical composition. Such compositions can be prepared using standard procedures.

Thus, the present invention further provides a pharmaceutical composition for use in the treatment of the above disorders which comprises the compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

The present invention further provides a pharmaceutical composition which comprises the compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

Compounds of formula (I) may be used in combination with other therapeutic agents, for example histamine H1 antagonists or medicaments claimed to be useful as either disease modifying or symptomatic treatments of Alzheimer's disease. Suitable examples of such other therapeutic agents may be agents known to modify cholinergic transmission such as 5-HT_6 antagonists, M1 muscarinic agonists, M2 muscarinic antagonists or acetylcholinesterase inhibitors. When the compounds are used in combination with other therapeutic agents, the compounds may be administered either sequentially or simultaneously by any convenient route.

The invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable derivative thereof together with a further therapeutic agent or agents.

The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical formulation and thus pharmaceutical formulations comprising a combination as defined above together with a pharmaceutically acceptable carrier or excipient comprise a further aspect of the invention. The individual components of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations.

When a compound of formula (I) or a pharmaceutically acceptable derivative thereof is used in combination with a second therapeutic agent active against the same disease state the dose of each compound may differ from that when the compound is used alone. Appropriate doses will be readily appreciated by those skilled in the art.

A pharmaceutical composition of the invention, which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable

or infusible solutions or suspensions or suppositories. Orally administrable compositions are generally preferred.

Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tabletting lubricants, disintegrants and acceptable wetting agents. The tablets may be coated according to methods well known in normal pharmaceutical practice.

Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and, if desired, conventional flavourings or colorants.

For parenteral administration, fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions, the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilisation cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

The composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration. The dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors. However, as a general guide suitable unit doses may be 0.05 to 1000 mg, more suitably 1.0 to 200 mg, and such unit doses may be administered more than once a day, for example two or three a day. Such therapy may extend for a number of weeks or months.

The following Descriptions and Examples illustrate the preparation of compounds of the invention.

Description 1

7-Benzyloxy-1,2,4,5-tetrahydro-benzo[*d*]azepine-3-carboxylic acid *tert*-butyl ester (D1)

7-Hydroxy-1,2,4,5-tetrahydro-benzo[*d*]azepine-3-carboxylic acid *tert*-butyl ester (PCT Int. Appl. (2002), WO 02/40471) (790mg, 3mmol), potassium carbonate (1.24g, 9mmol) and catalytic potassium iodide were suspended in 2-butanone (20ml). Benzyl bromide (536µL, 4.5mmol) was added and the mixture heated at reflux for 24 hours. The solids were filtered and then washed with acetone. The filtrate was concentrated *in vacuo* and the crude oil purified by column chromatography, eluting with a mixture of ethyl acetate and hexane (1:4) to afford the title compound (D1) (1.06g, 100%), ^{1}H NMR ($CDCl_3$) 7.44 (5H, m), 7.03 (1H, d, J 8.1Hz), 6.77 (1H, s), 6.74 (1H, dd, J 8.1 & 2.4 Hz), 3.49 (4H, m), 2.84 (4H, m), 1.48 (9H, s).

Description 2

7-Benzyloxy-1,2,4,5-tetrahydro-benzo[*d*]azepine (D2)

7-Benzyloxy-1,2,4,5-tetrahydro-benzo[*d*]azepine-3-carboxylic acid *tert*-butyl ester (D1) (1.06g, 3mmol) was dissolved in dichloromethane (15ml) and treated with trifluoroacetic acid (15ml). The solution was stirred at room temperature for 2 hours, concentrated *in vacuo* and then twice co-evaporating with dichloromethane. The residue was dissolved in methanol and applied to a SCX (Varian bond-elute, 10g) and washed with methanol and then a mixture of .880 ammonia/ methanol. The combined basic fractions were reduced in vacuo and the residue purified by column chromatography (1:9:40 .880 ammonia:ethanol:dichloromethane) to afford the title compound (D2) (702mg, 93%), MS (ES+) m/e 254 $[M+H]^+$.

Description 3 (D3)

4-(3-Cyclopentyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidine-1-carboxylic acid-*tert*-butyl ester (D3)



3-Cyclopentyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (E4) (1.1 g, 4.8 mmol), 4-hydroxy-piperidine-1-carboxylic acid *tert*-butyl ester (1.15 g, 5.7 mmol), di-tert-butyl azodicarboxylate (1.31 g, 5.7 mmol) and triphenylphosphine (1.5 g, 5.7 mmol) were stirred at room temperature for 16 hours in tetrahydrofuran (20 ml). The mixture was acidified with acetic acid and applied to a SCX cartridge (Varian bond-elute, 10 g) and washed with methanol and then a mixture of .880 ammonia/methanol. The combined basic fractions were concentrated *in vacuo* and the resulting residue was purified by column chromatography (1:9:90 .880 ammonia:methanol:dichloromethane) to afford the title product (D3). MS (ES+) m/e 415 $[M+H]^+$.

Description 4

7-(4-Methoxycarbonyl-benzyloxy)-1,2,4,5-tetrahydro-benzo[*d*]azepine-3-carboxylic acid *tert*-butyl ester (D4)



7-Hydroxy-1,2,4,5-tetrahydro-benzo[*d*]azepine-3-carboxylic acid *tert*-butyl ester (WO 02/40471) (5.27 g, 20.0 mmol), potassium carbonate (8.30 g, 60.0 mmol) and catalytic potassium iodide were suspended in butanone (100 ml). Methyl 4-(bromomethyl) benzoate (5.5 g, 24.0 mmol) dissolved in butanone (50 ml) was added dropwise after which the reaction mixture was stirred at reflux for 24 hours. The reaction mixture was cooled, the solids were filtered and then washed with acetone. The filtrate was concentrated in vacuo and the crude mixture was purified by column chromatography (1:4 ethyl acetate:hexane) to afford the title compound (D4). MS (ES+) m/e 344 $[(M+H)^+ - CO_2{}^tBu]^+$.

Description 5

4-(2,3,4,5-Tetrahydro-1*H*-benzo[*d*]azepin-7-yloxymethyl)-benzoic acid methyl ester (D5)



7-(4-Methoxycarbonyl-benzyloxy)-1,2,4,5-tetrahydro-benzo[*d*]azepine-3-carboxylic acid *tert*-butyl ester (D4) (6.35 g) was dissolved in dichloromethane (30 ml) and treated with trifluoroacetic acid (30 ml). The solution was stirred at room temperature for 2 hours, concentrated in vacuo and then twice co-evaporated with dichloromethane. The residue was dissolved in dichloromethane and washed with 10% aqueous sodium hydroxide, water and brine. The organic layer was dried over magnesium sulfate, filtered and concentrated in vacuo to afford the title compound (D5).

Description 6

1-(6-Chloro-pyridin-3-yl)-1-morpholin-4-yl-methanone (D6)



Morpholine (0.2 ml, 2.2 mmol) was added to stirred solution of 6-chloronicotinyl chloride (250 mg, 1.4 mmol) in dichloromethane (10 ml). After 2 hours the reaction was allowed to cool and the crude mixture was applied to a SCX cartridge (Varian bond-elute, 10 g) and washed with methanol. The methanolic fractions were concentrated in vacuo to afford the title compound (D6).

Descriptions 7-32 (D7-D32)

Descriptions 7-32 (D7-D32) were prepared and used without further characterisation using the method described for Description 6 (D6) from the appropriate chloride and amine indicated in the table:

Description	Chloride	Amine
1-(6-Chloro-pyridin-3-yl)-1-pyrrolidin-1-yl-methanone (D7)	6-Chloronicotinyl chloride	Pyrrolidine
6-Chloro-nicotinamide (D8)	6-Chloronicotinyl chloride	Ammonia
6-Chloro-*N,N*-dimethyl-nicotinamide (D9)	6-Chloronicotinyl chloride	Dimethylamine
6-Chloro-*N*-ethyl-*N*-methyl-nicotinamide (D10)	6-Chloronicotinyl chloride	N-Ethylmethyl-amine
6-Chloro-*N*-methyl-nicotinamide (D11)	6-Chloronicotinyl chloride	Methylamine
6-Chloro-*N*-cyclopentyl-nicotinamide (D12)	6-Chloronicotinyl chloride	Cyclopentylamine
1-(6-Chloro-pyridin-3-yl)-1-piperidin-1-yl-methanone (D13)	6-Chloronicotinyl chloride	Piperidine
1-(2-Chloro-pyridin-4-yl)-1-piperidin-1-yl-methanone (D14)	2-Chloro-isonicotinoyl chloride	Piperidine
1-(2-Chloro-pyridin-4-yl)-1-pyrrolidin-1-yl-methanone (D15)	2-Chloro-isonicotinoyl chloride	Pyrrolidine
1-(2-Chloro-pyridin-4-yl)-1-morpholin-4-yl-methanone (D16)	2-Chloro-isonicotinoyl chloride	Morpholine
1-(6-Chloro-pyridin-2-yl)-1-piperidin-1-yl-methanone (D17)	6-Chloro-pyridine-2-carbonyl chloride	Piperidine
1-(6-Chloro-pyridin-2-yl)-1-(1,1-dioxothiomorpholin-4-yl)-methanone (D18)	6-Chloro-pyridine-2-carbonyl chloride	Thiomorpholine 1,1-dioxide
1-(6-Chloro-pyridin-2-yl)-1-pyrrolidin-1-yl-methanone (D19)	6-Chloro-pyridine-2-carbonyl chloride	Pyrrolidine
1-(6-Chloro-pyridin-2-yl)-1-morpholin-4-yl-methanone (D20)	6-Chloro-pyridine-2-carbonyl chloride	Morpholine
1-(2-Chloro-pyridin-3-yl)-1-morpholin-4-yl-methanone (D21)	2-Chloro-nicotinoyl chloride	Morpholine
1-(2-Chloro-pyridin-3-yl)-1-piperidin-1-yl-methanone (D22)	2-Chloro-nicotinoyl chloride	Piperidine
1-(4-Chloro-phenyl)-1-morpholin-4-yl-methanone (D23)	4-Chloro-benzoyl chloride	Morpholine
4-Chloro-N-cyclopropylmethyl-benzamide (D24)	4-Chloro-benzoyl chloride	Cyclopropylmethyl-amine

1-(4-Chloro-phenyl)-1-pyrrolidin-1-yl-methanone (D25)	4-Chloro-benzoyl chloride	Pyrrolidine
4-Chloro-N-cyclobutyl-benzamide (D26)	4-Chloro-benzoyl chloride	Cyclobutylamine
4-Chloro-*N,N*-diethyl-benzamide (D27)	4-Chloro-benzoyl chloride	Diethylamine
4-Chloro-*N*-(2-cyano-ethyl)-*N*-methyl-benzamide (D28)	4-Chloro-benzoyl chloride	3-Methylamino-propionitrile
1-(3-Chloro-phenyl)-1-morpholin-4-yl-methanone (D29)	3-Chloro-benzoyl chloride	Morpholine
3-Chloro-N-cyclopropylmethyl-benzamide (D30)	3-Chloro-benzoyl chloride	Cyclopropylmethyl-amine
4-(4-Chloro-benzenesulfonyl)-morpholine (D31)	4-Chloro-benzenesulfonyl chloride	Morpholine
4-Chloro-*N,N*-diethyl-benzenesulfonamide (D32)	4-Chloro-benzenesulfonyl chloride	Diethylamine

Description 33

5-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-pyrazine-2-carboxylic acid (D33)



5-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-pyrazine-2-carboxylic acid methyl ester (E122) (880 mg, 2.5 mmol) was dissolved in a mixture of ethanol (15 ml) and 2*N* sodium hydroxide (4 ml). The resulting mixture was stirred at room temperature for 0.5 hours and then concentrated in vacuo to remove the organic solvents. The reaction mixture was then acidified to pH 5 (2N hydrochloric acid) and the resulting precipitates were filtered, washed with water and dried under vacuum to afford the title compound (D33). MS (ES+) m/e 340 $[M+H]^+$.

Description 34

5-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-pyrazine-2-carbonyl chloride (D34)



Thionyl chloride (5 ml) was added slowly to 5-(3-cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-pyrazine-2-carboxylic acid (D33) (485 mg). The resulting reaction mixture was stirred at room temperature for 1 hour and then heated at reflux for a further 1 hour. The reaction mixture was cooled, diluted with toluene and concentrated

in vacuo to afford the title compound (D34), which was used without further characterisation.

Example 1

7-Benzyloxy-3-cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[d]azepine (E1)



7-Benzyloxy-1,2,4,5-tetrahydro-benzo[*d*]azepine (D2) (25.3 g, 100 mmol) was dissolved in 2.5% acetic acid in dichloromethane (400 ml) at 0 °C and treated dropwise with cyclobutanone (11.2 ml, 150 mmol). The mixture was stirred for 30 minutes and then sodium triacetoxyborohydride (31.8 g, 150 mmol) was added portion wise. The reaction mixture was stirred at room temperature for 4 hours, basified with saturated sodium carbonate solution and extracted with dichloromethane. The combined extracts were washed with water, brine, dried over anhydrous sodium sulfate and concentrated in vacuo. The crude residue was triturated with hexane and filtered to afford the title product (E1). MS (ES+) m/e 308 $[M+H]^+$.

Example 2

7-Benzyloxy-3-cyclopentyl-2,3,4,5-tetrahydro-1*H*-benzo[d]azepine (E2)

Example 2 was prepared using the method described for Example 1, substituting cyclobutanone for cyclopentanone. MS (ES+) m/e 322 $[M+H]^+$.

Example 3

3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[d]azepin-7-ol (E3)



7-Benzyloxy-3-cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine (E1) (9.22 g, 30 mmol) was dissolved in ethanol (150 ml) and tetrahydrofuran (50 ml). Palladium (1.5 g, 10% on charcoal paste) was added and the reaction mixture was stirred at room temperature under hydrogen (1 atmosphere) for 5 hours. The reaction mixture was filtered through celite and the filtrate concentrated in vacuo. The crude residue was triturated with diethyl ether and filtered to afford the title product (E3), which was used in subsequent steps without further purification. MS (ES+) m/e 218 $[M+H]^+$.

Example 4

3-Cyclopentyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (E4)

Example 4 was prepared using the method described for Example 3 (E3), substituting 7-benzyloxy-3-cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine (E1) for 7-benzyloxy-3-cyclopentyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine (E2).
^{1}H NMR (DMSO, d6) 9.08 (1H, brs), 6.70 (1H, d), 6.53-6.47 (2H, m), 3.31-2.50 (9H, m) 1.88-1.43 (8H, m).

Example 5

3-Cyclopentyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E5)



4-(3-Cyclopentyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidine-1-carboxylic acid-*tert*-butyl ester (D3) (593 mg, 1.43 mmol) was dissolved in dichloromethane (5 ml) and treated with trifluoroacetic acid (3 ml). The solution was stirred at room temperature for 1 hour, concentrated in vacuo and applied to a SCX cartridge (Varian bond-elute, 5 g) and washed with methanol and then a mixture of .880 ammonia/ methanol. The combined basic fractions were concentrated in vacuo and the resulting residue was purified by column chromatography eluting with 1: 9: 90 .880 ammonia: methanol: dichloromethane to afford the title product (E5). MS (ES+) m/e 315 $[M+H]^+$.

Examples 6-12

Examples 6-12 (E6-12) were prepared using an analogous method to that described for Example 5 (E5) from either 3-cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (E3) or 3-cyclopentyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (E4) and the appropriate alcohol indicated in the table.

Example	Starting Material	Alcohol	LC/MS ($M+H^+$)
3-Cyclobutyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E6)	E3	4-Hydroxy-piperidine-1-carboxylic acid *tert*-butyl ester	301
3-Cyclobutyl-7-(piperidin-4-ylmethoxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E7)	E3	4-Hydroxymethyl-piperidine-1-carboxylic acid *tert*-butyl ester	315
3-Cyclobutyl-7-((*R*)-1-pyrrolidin-2-ylmethoxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E8)	E3	(*R*)-2-Hydroxymethyl-pyrrolidine-1-carboxylic acid *tert*-butyl ester	301
3-Cyclobutyl-7-((*R*)-pyrrolidin-3-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E9)	E3	(*R*)-3-Hydroxy-pyrrolidine-1-carboxylic acid *tert*-butyl ester	287
3-Cyclobutyl-7-((*S*)-pyrrolidin-3-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E10)	E3	(*S*)-3-Hydroxy-pyrrolidine-1-carboxylic acid *tert*-butyl ester	287
3-Cyclobutyl-7-((*S*)-1-pyrrolidin-2-ylmethoxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E11)	E3	(*S*)-2-Hydroxymethyl-pyrrolidine-1-carboxylic acid *tert*-butyl ester	301

3-Cyclopentyl-7-(piperidin-4-ylmethoxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E12)	E4	4-Hydroxymethyl-piperidine-1-carboxylic acid *tert*-butyl ester	329

Example 13
4-{1-[4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidin-1-yl]-methanoyl}-benzonitrile (E13)



4-Cyanobenzoic acid (147 mg, 1 mmol), 1-hydroxy benzotriazole hydrate (154 mg, 1 mmol) and N-cyclohexylcarbodiimide N'-methyl polystyrene (1.8 mmol/g, 555 mg, 1 mmol) were stirred at room temperature in dichloromethane (5 ml) for 15 minutes. 3-cyclobutyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E6) (150 mg, 0.5 mmol) was added and stirring continued for 16 hours. The reaction mixture was applied to a SCX cartridge (Varian bond-elute, 5 g) and washed with methanol and then a mixture of .880 ammonia/methanol. The combined basic fractions were concentrated in vacuo and the resulting residue was purified by column chromatography (dichloromethane to 1:9:90 .880 ammonia:ethanol:dichloromethate) to afford the title product (E13). MS (ES+) m/e 430 $[M+H]^+$.

Examples 14-42
Examples 14-42 (E14-E42) were prepared using an analogous method to that described for Example 13 (E13) from the appropriate amine and acid indicated in the table:

Example	Amine	Acid	LC/MS ($M+H^+$)
1-[4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidin-1-yl]-1-(tetrahydro-pyran-4-yl)-methanone (E14)	3-Cyclobutyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E6)	Tetrahydro-pyran-4-carboxylic acid	413
1-[4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidin-1-yl]-1-cyclohexyl-methanone (E15)	3-Cyclobutyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E6)	Cyclohexane carboxylic acid	411
1-[4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidin-1-yl]-1-isoquinolin-1-yl-methanone (E16)	3-Cyclobutyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine	Isoquinoline-1-carboxylic acid	456

	(E6)		
4-{(*E*)-3-[4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidin-1-yl]-3-oxo-propenyl}-benzonitrile (E17)	3-Cyclobutyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E6)	(E)-3-(4-Cyano-phenyl)-acrylic acid	456
1-[4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidin-1-yl]-1-isoquinolin-6-yl-methanone (E18)	3-Cyclobutyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E6)	Isoquinoline-6-carboxylic acid	456
1-[4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidin-1-yl]-1-(5-methyl-isoxazol-3-yl)-methanone (E19)	3-Cyclobutyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E6)	5-Methyl-isoxazole-3-carboxylic acid	410
1-Benzothiazol-6-yl-1-[4-(3-cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidin-1-yl]-methanone (E20)	3-Cyclobutyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E6)	Benzothiazole-6-carboxylic acid	462
1-[4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidin-1-yl]-1-pyridin-4-yl-methanone (E21)	3-Cyclobutyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E6)	Isonicotinic acid	406
1-[4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidin-1-yl]-1-[4-(1-pyrrolidin-1-yl-methanoyl)-phenyl]-methanone (E22)	3-Cyclobutyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E6)	4-(1-Pyrrolidin-1-yl-methanoyl)-benzoic acid PCT Int. Appl. (2003), WO 0304468 A1	502
1-[4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidin-1-yl]-1-thiophen-3-yl-methanone (E23)	3-Cyclobutyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine	Thiophene-3-carboxylic acid	411

	(E6)		
1-[4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidin-1-yl]-1-furan-3-yl-methanone (E24)	3-Cyclobutyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E6)	Furan-3-carboxylic acid	395
1-[4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxymethyl)-piperidin-1-yl]-1-tetrahydro-pyran-4-yl)-methanone (E25)	3-Cyclobutyl-7-(piperidin-4-ylmethoxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E7)	Tetrahydro-pyran-4-carboxylic acid	427
1-[(*R*)-2-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxymethyl)-pyrrolidin-1-yl]-1-(tetrahydro-pyran-4-yl)-methanone (E26)	3-Cyclobutyl-7-((*R*)-1-pyrrolidin-2-ylmethoxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E8)	Tetrahydro-pyran-4-carboxylic acid	413
1-[(*R*)-3-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-pyrrolidin-1-yl]-1-(tetrahydro-pyran-4-yl)-methanone (E27)	3-Cyclobutyl-7-((*R*)-pyrrolidin-3-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E9)	Tetrahydro-pyran-4-carboxylic acid	399
1-[(*S*)-3-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-pyrrolidin-1-yl]-1-(tetrahydro-pyran-4-yl)-methanone (E28)	3-Cyclobutyl-7-((*S*)-pyrrolidin-3-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E10)	Tetrahydro-pyran-4-carboxylic acid	399
1-[(*S*)-2-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-pyrrolidin-1-yl]-1-(tetrahydro-pyran-4-yl)-methanone (E29)	3-Cyclobutyl-7-((*S*)-1-pyrrolidin-2-ylmethoxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E11)	Tetrahydro-pyran-4-carboxylic acid	413
1-[4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidin-1-yl]-1-(methanesulfonyl-phenyl)-methanone (E30)	3-Cyclobutyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E6)	4-Methanesulfonyl-benzoic acid	483
1-[4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidin-1-yl]-1-pyrazin-2-yl-methanone (E31)	3-Cyclobutyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E6)	2-Pyrazine carboxylic acid	407

5-{1-[4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidin-1-yl]-methanoyl}-1*H*-pyridone (E32)	3-Cyclobutyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E6)	6-Hydroxy nicotinic acid	422
1-[4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidin-1-yl]-1-(2,3-dihydro-benzofuran-5-yl)-methanone (E33)	3-Cyclobutyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E6)	2,3-Dihydro-benzofuran-5-carboxylic acid	447
1-[4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidin-1-yl]-3-methoxy-propan-1-one (E34)	3-Cyclobutyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E6)	3-Methoxy-propionic acid	387
1-[4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidin-1-yl]-(2,3-dihydro-benzofuran-7-yl)-methanone (E35)	3-Cyclobutyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E6)	2,3-Dihydro-benzofuran-7-carboxylic acid	447
4-{1-{4-(3-Cyclopentyl-7-(piperidin-4-ylmethoxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxymethyl)piperidin-1-yl]-methanoyl}-benzonitrile (E36)	3-Cyclopentyl-7-(piperidin-4-ylmethoxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E12)	4-Cyano-benzoic acid	458
1-[4-(3-Cyclopentyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxymethyl)-piperidin-1-yl]-1-[4-(1-pyrrolidin-1-yl-methanoyl)-phenyl]-methanone (E37)	3-Cyclopentyl-7-(piperidin-4-ylmethoxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E12)	4-(1-Pyrrolidin-1-yl-methanoyl)-benzoic acid	530
4-{1-[4-(3-Cyclopentyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidin-1-yl]-methanoyl}-benzonitrile (E38)	3-Cyclopentyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E5)	4-Cyano-benzoic acid	444

1-[4-(3-Cyclopentyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidin-1-yl]-1-pyridin-4-yl-methanone (E39)	3-Cyclopentyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E5)	Isonicotinic acid	420
1-[4-(3-Cyclopentyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidin-1-yl]-1-quinolin-6-yl-methanone (E40)	3-Cyclopentyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E5)	Quinoline-6-carboxylic acid	470
1-[4-(3-Cyclopentyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidin-1-yl]-1-[4-(1-pyrrolidin-1-yl-methanoyl)-phenyl]methanone (E41)	3-Cyclopentyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E5)	4-(1-Pyrrolidin-1-yl-methanoyl)-benzoic acid	516
1-Biphenyl-4-yl-1-[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidin-1-yl]-methanone (E42)	3-Cyclopentyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E5)	4-Biphenyl carboxylic acid	495

Example 43
1-[4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidin-1-yl]-1-cyclopentyl-methanone (E43)



3-Cyclobutyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E6) (150 mg, 0.5 mmol) was stirred in dichloromethane (5 ml) with diethylaminomethyl polystyrene (3.2 mmol/g, 625 mg, 2 mmol). Cyclopentane carbonyl chloride (80 µl, 0.6 mmol) was added and the mixture stirred at room temperature for 16 hours. The resin was filtered, washed with dichloromethane and the filtrate concentrated in vacuo. The residue was purified by column chromatography (dichloromethane to 1:9:90 .880 ammonia:ethanol:dichloromethane) to afford the title product (E43). MS (ES+) m/e 397 $[M+H]^+$.

Examples 44-51
Examples 44-51 (E44-E51) were prepared using an analogous method to that described for Example 43 (E43) from the appropriate amine and carbonyl chloride indicated in the table:

Example	Amine	Carbonyl	LC/MS

		chloride	$(M+H^+)$
4-{1-[4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxymethyl)-piperidin-1-yl]-methanoyl}-benzonitrile (E44)	3-Cyclobutyl-7-(piperidin-4-ylmethoxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E7)	4-Cyano benzoyl chloride	444
4-{1-[(*R*)-2-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxymethyl)-pyrrolidin-1-yl]-methanoyl}-benzonitrile (E45)	3-Cyclobutyl-7-((*R*)-1-pyrrolidin-2-ylmethoxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E8)	4-Cyano benzoyl chloride	430
4-{1-[(*R*)-3-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-pyrrolidin-1-yl]-methanoyl}-benzonitrile (E46)	3-Cyclobutyl-7-((*R*)-pyrrolidin-3-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E9)	4-Cyano-benzoyl chloride	416
4-{1-[(*S*)-3-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-pyrrolidin-1-yl]-methanoyl}-benzonitrile (E47)	3-Cyclobutyl-7-((*S*)-pyrrolidin-3-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E10)	4-Cyano-benzoyl chloride	416
4-{1-[(*S*)-2-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-pyrrolidin-1-yl]-methanoyl}-benzonitrile (E48)	3-Cyclobutyl-7-((*S*)-1-pyrrolidin-2-ylmethoxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E11)	4-Cyano-benzoyl chloride	430
1-[4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidin-1-yl]-2,2-dimethyl-propan-1-one (E49)	3-Cyclobutyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E6)	2,2-Dimethyl-propionyl chloride	385
1-[4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidin-1-yl]-1-cyclopropyl-methanone (E50)	3-Cyclobutyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E6)	Cyclopropane carbonyl chloride	369
1-Cyclobutyl-1-[4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxy)-piperidine-1-yl]-methanone (E51)	3-Cyclobutyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E6)	Cyclobutane carbonyl chloride	384

Example 52

4-{1-{4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidin-1-yl]-1-morpholin-4-yl-methanone (E52)



3-Cyclobutyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E6) (150 mg, 0.5 mmol) was stirred in dichloromethane (5 ml) with diethylaminomethyl polystyrene (3.2 mmol/g, 625 mg, 2 mmol). Morpholine carbamoyl chloride (70 µL, 0.6 mmol) was added and the mixture stirred at room temperature for 16 hours. The resin was filtered, washed with dichloromethane and the filtrate concentrated in vacuo. The residue was purified by column chromatography (dichloromethane to 1:9:90 .880 ammonia:ethanol:dichloromethane) to afford the title product (E52). MS (ES+) m/e 414 $[M+H]^+$.

Examples 53-60

Examples 53-60 (E53-E60) were prepared using an analogous method to that described for Example 52 (E52) from the appropriate amine and carbonyl chloride indicated in the table:

Example	Amine	Carbonyl Chloride	LC/MS ($M+H^+$)
1-[4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxymethyl)-piperidin-1-yl]-1-morpholin-4-yl-methanone (E53)	3-Cyclobutyl-7-(piperidin-4-ylmethoxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E7)	Morpholine -4-carbonyl chloride	428
1-[(*R*)-2-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxymethyl)-pyrrolidin-1-yl]-1-morpholin-4-yl-methanone (E54)	3-Cyclobutyl-7-((*R*)-1-pyrrolidin-2-ylmethoxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E8)	Morpholine -4-carbonyl chloride	414
1-[(*R*)-3-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-pyrrolidin-1-yl]-1-morpholin-4-yl-methanone (E55)	3-Cyclobutyl-7-((*R*)-pyrrolidin-3-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E9)	Morpholine -4-carbonyl chloride	400
1-[(*S*)-3-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-pyrrolidin-1-yl]-1-morpholin-4-yl-methanone (E56)	3-Cyclobutyl-7-((*S*)-pyrrolidin-3-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E10)	Morpholine -4-carbonyl chloride	400

4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidine-1-carboxylic acid diisopropylamide (E57)	3-Cyclobutyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E6)	Diisopropyl-carbonyl chloride	429
1-[4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidin-1-yl]-pyrrolidin-1-yl-methanone (E58)	3-Cyclobutyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E6)	Pyrrolidine-1-carbonyl chloride	398
1-[4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidin-1-yl]-1-piperidin-1-yl-methanone (E59)	3-Cyclobutyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E6)	Piperidine-1-carbonyl chloride	412
1-[(*S*)-2-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxymethyl)-pyrrolidin-1-yl]-1-morpholin-4-yl-methanone (E60)	3-Cyclobutyl-7-((*S*)-1-pyrrolidin-2-ylmethoxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E11)	Morpholine-4-carbonyl chloride	414

Example 61

4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidine-1-carboxylic acid diethylamide (E61)



3-Cyclobutyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E6) (1.5 g, 5 mmol) dissolved in toluene (40 ml) was added slowly to a 20% phosgene in toluene solution (12.5 ml, 25 mmol) at 0 °C. The mixture was stirred at room temperature for 3 hours and concentrated in vacuo to afford a crude residue (1.91 g) that was used without further purification. The crude product (300 mg, 0.75 mmol) was added to a stirred slurry of diethylamine (207 µL, 2 mmol) and diethylaminomethyl polystyrene (3.2 mmol/g, 1.41 g, 4.5 mmol) in dichloromethane (10 ml). The reaction mixture was stirred at room temperature for 16 hours, filtered and concentrated in vacuo. The crude residue was purified by column chromatography (dichloromethane to 1:9:90 .880 ammonia:ethanol:dichloromethane) to afford the title product (E61). MS (ES+) m/e 400 $[M+H]^+$.

Examples 62-65

Examples 62-65 (E62-E65) were prepared using an analogous method to that described for Example 61 (E61) from 3-cyclobutyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E6) and the appropriate amine indicated in the table:

Example	Amine	LC/MS ($M+H^+$) Unless stated
1-[4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidin-1-yl]-1-(1,3-dihydro-isoindol-2-yl)-methanone (E62)	2,3-Dihydro-1*H*-isoindole	446
1-[4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidin-1-yl]-1-(2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl)-methanone (E63)	3,4,5,6-Tetrahydro-2*H*-[1,2']bipyrazinyl	491
1-[4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidine-1-carboxylic acid isopropyl-(2-methoxy-ethyl) amide (E64)	Isopropyl-(2-methoxy-ethyl-amine	444
1-[4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidin-1-yl]-(1,1-dioxo-thiomorpholin-4-yl)-methanone (E65)	Thiomorpholine 1,1-dioxide	462

Example 66

4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidine-1-carboxylic acid isopropylamide (E66)



A solution of 3-cyclobutyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E6) (150 mg, 0.5 mmol) and isopropyl isocyanate (60 µL, 0.6 mmol) in dichloromethane (5 ml) was stirred at room temperature for 16 hours. The solution was concentrated in vacuo and the residue was purified by column chromatography (dichloromethane to 1:9:90 .880 ammonia:ethanol:dichloromethane to afford the title product (E66). MS (ES+) m/e 386 $[M+H]^+$.

Example 67

4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidine-1-carboxylic acid (4-fluoro-phenyl)-amide (E67)

Example 67 was prepared using the method described for Example 66 (E66) substituting isopropyl-isocyanate for the 4-fluoro-isocyanate. MS (ES+) m/e 438 $[M+H]^+$.

Example 68

2-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-*N,N*-dimethyl-acetamide (E68)



Sodium hydride (60% disp. in mineral oil, 60 mg, 1.5 mmol) was added to a stirred solution of 3-cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (E3) (200 mg, 0.9 mmol) in dimethyl sulfoxide (10 ml). After 0.5 hours, dimethyl amino acetyl chloride (0.3 ml, 2.4 mmol) was added and the reaction mixture was heated to 120 °C for 6 hours. The reaction was allowed to cool, the crude mixture was applied to a SCX cartridge (Varian bond-elute, 10 g) and washed with methanol and then a mixture of .880 ammonia/methanol. The combined basic fractions were reduced in vacuo to afford the title compound (E68). MS (ES+) m/e 303 $[M+H]^+$.

Examples 69-71

Examples 69-71 (E69-E71) were prepared using the method described for Example 68 (E68) from 3-cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (E3) and the appropriate chloride indicated in the table.

Example	Chloride	LC/MS ($M+H^+$)
2-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-*N*-phenyl-acetamide (E69)	2-Chloro-*N*-phenyl-acetamide	351
2-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-1-pyrrolidin-1-yl-ethanone (E70)	2-Chloro-1-pyrrolidin-1-yl-ethanone	329
2-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-1-morpholin-4-yl-ethanone (E71)	2-Chloro-1-morpholinyl-4-yl-ethanone	345

Example 72

3-Cyclobutyl-7-(1-methanesulfonyl-piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E72)



3-Cyclobutyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E6) (150 mg, 0.5 mmol) was stirred in dichloromethane (5 ml) with diethylaminomethyl polystyrene (3.2 mmol/g, 625 mg, 2 mmol). Methane sulfonyl chloride (43 μL, 0.55 mmol) was added and the mixture stirred at room temperature for 16 hours. The resin was filtered, washed with dichloromethane and the filtrate concentrated in vacuo. The residue was purified by column chromatography (1:9:90 .880 ammonia:ethanol:dichloromethane) to afford the title product (E72). MS (ES+) m/e 379 $[M+H]^+$.

Examples 73-78

Examples 73-78 (E73-E78) were prepared using an analogous method to that described for Example 72 (E72) from the appropriate amine and sulfonyl chloride indicated in the table:

Example	Amine	Sulfonyl Chloride	LC/MS ($M+H^+$)
4-[4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-piperidine-1-sulfonyl]-benzonitrile (E73)	3-Cyclobutyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E6)	4-Cyano-benzenesulfonyl chloride	466
3-Cyclobutyl-7-[1-(3,5-dimethyl-isoxazole-4-sulfonyl)-piperidin-4-yloxy]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E74)	3-Cyclobutyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E6)	3,5-Dimethyl-isoxazole-4-sulfonyl chloride	460
4-[4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxymethyl)-piperidine-1-sulfonyl]-benzonitrile (E75)	3-Cyclobutyl-7-(piperidin-4-ylmethoxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E7)	4-Cyano-benzenesulfonyl chloride	480
4-[(*R*)-2-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxymethyl)-pyrrolidine-1-sulfonyl]-benzonitrile (E76)	3-Cyclobutyl-7-((*R*)-1-pyrrolidin-2-ylmethoxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E8)	4-Cyano-benzenesulfonyl chloride	466
4-[(*R*)-3-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-pyrrolidine-1-sulfonyl]-benzonitrile (E77)	3-Cyclobutyl-7-((*R*)-pyrrolidin-3-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E9)	4-Cyano-benzenesulfonyl chloride	452
4-[(*S*)-3-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-pyrrolidine-1-sulfonyl]-benzonitrile (E78)	3-Cyclobutyl-7-((*S*)-pyrrolidin-3-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E10)	4-Cyano-benzenesulfonyl chloride	452

Example 79

3-Cyclobutyl-7-(2,4-difluoro-benzyloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E79)



Potassium carbonate (778 mg, 5.6 mmol) was added to a stirred solution of 3-cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[d]azepin-7-ol (E3) (868 mg, 4.0 mmol), 2,4-difluorobenzyl bromide (0.25 ml, 2.1 mmol) and potassium iodide (25 mg) in butanone (9 ml). The reaction mixture was stirred at reflux for 18 hours, cooled, filtered and concentrated in vacuo. The crude residue was dissolved with ethyl acetate and washed with water and brine. The organic layer was dried over magnesium sulfate, filtered and concentrated in vacuo. Purification of the resulting residue by column chromatography (0.25:2.25:97.5 to 1:9:10 .880 ammonia: ethanol: dichloromethane) afforded the title compound (E79). MS (ES+) m/e 344 $[M+H]^+$.

Examples 80-87

Examples 80-87 (E80-E87) were prepared using the general base catalysed method described for Example 80 (E80) from 3-cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[d]azepin-7-ol (E3) and the appropriate halide indicated in the table:

Example	Halide	LC/MS ($M+H^+$)
3-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxymethyl)-benzonitrile (E80)	3-Bromomethyl-benzonitrile	333
3-Cyclobutyl-7-(3-methoxy-benzyloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E81)	1-Bromomethyl-3-methoxybenzene	338
3-Cyclobutyl-7-(pyridin-2-ylmethoxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E82)	2-Bromomethyl-pyridine	309
3-Cyclobutyl-7-(pyridin-3-ylmethoxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E83)	3-Bromomethyl-pyridine	309
3-Cyclobutyl-7-(pyridin-4-ylmethoxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E84)	4-Bromomethyl-pyridine	309
2-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxymethyl)-benzonitrile (E85)	2-Bromomethyl-benzonitrile	333
4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxymethyl)-benzonitrile (E86)	4-Bromomethyl-benzonitrile	333
6-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxymethyl)-1-methyl-1*H*-quinolin-2-one (E87)	6-Bromomethyl-1-methyl-1*H*-quinolin-2-one	389

Example 88

4-(3-Cyclopentyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxymethyl)-benzoic acid methyl ester (E88)



4-(2,3,4,5-Tetrahydro-1*H*-benzo[*d*]azepin-7-yloxymethyl)-benzoic acid methyl ester (D5) (2.83 g, 9.1 mmol) and cyclopentanone (1.6 ml, 18.2 mmol) were dissolved in dichloromethane (30 ml) and acetic acid (0.5 ml). Sodium triacetoxy borohydride (3.85 g, 18.2 mmol) was added and the solution was stirred at room temperature for 4 hours. The reaction mixture was washed with a saturated solution of sodium carbonate, the organic layer was dried over magnesium sulfate, filtered and concentrated in vacuo. The crude mixture was purified by column chromatography (1:9:90 .880 ammonia:ethanol:dichloromethane) to afford the title compound (E88). MS (ES+) m/e 378 $[M+H]^+$.

Example 89

4-(3-Cyclopentyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxymethyl)-benzoic acid (E89)



4-(3-Cyclopentyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxymethyl)-benzoic acid methyl ester (E88) (3.1 g, 8.1 mmol)) was dissolved in a mixture of methanol (90 ml), 2N sodium hydroxide (12 ml) and water (30 ml). The resulting mixture was stirred at 60 °C for 4 hours and then cooled to room temperature. The mixture was concentrated in vacuo to remove the organic solvents and then acidified to pH 6 (2N hydrochloric acid). The resulting precipitates were filtered, washed with water and dried under vacuum to afford the title compound (E89). MS (ES+) m/e 366 $[M+H]^+$.

Example 90

1-[4-(3-Cyclopentyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxymethyl)-phenyl]-1-pyrrolidin-yl-methanone (E90)



4-(3-Cyclopentyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxymethyl)-benzoic acid (E89) (0.201 mg, 0.55 mmol)), 1,3-diisopropylcarbodiimide (44 µl, 0.6 mmol) and 1-hydroxybenzotriazole hydrate (82 mg, 0.6 mmol) were dissolved in a mixture of dichloromethane (2 ml) and dimethyl formamide (1 ml). After stirring at room temperature for 0.5 hours, pyrrolidine (41 µl, 0.5 mmol) was added and the resulting mixture was allowed to stir for 16 hours. The crude reaction was applied to a SCX cartridge (Varian bond-elute, 5 g) and washed with methanol and then a mixture of .880

ammonia/ methanol. The combined basic fractions were concentrated in vacuo, and the resulting residue was purified by column chromatography (1:9:90 .880 ammonia:ethanol:dichloromethane) to afford the title compound (E90). MS (ES+) m/e 419 $[M+H]^+$.

Examples 91-93

Examples 91-93 (E91-E93) were prepared using an analogous method to that described for Example 90 (E90) from 4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxymethyl)-benzoic acid (E89) and the appropriate amine indicated in the table:

Example	Amine	LC/MS ($M+H^+$)
1-[4-(3-Cyclopentyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxymethyl)-phenyl]-1-morpholin-4-yl-methanone (E91)	Morpholine	435
1-[4-(3-Cyclopentyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxymethyl)-phenyl]-1-(4-pyridin-4-yl-piperazin-1-yl)-methanone (E92)	1-Pyridin-4-yl-piperazine	511
1-[4-(3-Cyclopentyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxymethyl)-phenyl]-1-[4-(4-fluoro-phenyl)-piperazin-1-yl]-methanone (E93)	1-(4-Fluoro-phenyl)-piperazine	528

Example 94

3-(3-Cyclopentyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxymethyl)-benzoic acid methyl ester (E94)



Example 94 (E94) was prepared following the descriptions outlined for Example 88 (E88) substituting 4-bromomethyl-benzoic acid methyl ester for 3-bromomethyl-benzoic acid methyl ester. MS (ES+), m/e 380 $[M+H]^+$.

Example 95

3-(3-Cyclopentyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxymethyl)-benzoic acid (E95)



Example 95 (E95) was prepared using the procedure outlined for Example 89 (E89) substituting 4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxymethyl)-benzoic acid methyl ester (E88) for 3-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxymethyl)-benzoic acid methyl ester (E94). MS (ES+), m/e 366 $[M+H]^+$.

Example 96
1-[3-(3-Cyclopentyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxymethyl)-phenyl]-1-pyrrolidin-yl-methanone (E96)



Example 96 (E96) was prepared using the procedure outlined for Example 90 (E90) substituting 4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxymethyl)-benzoic acid (E89) for 3-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxymethyl)-benzoic acid (E95). MS (ES+), m/e 419 $[M+H]^+$.

Examples 97-99

Examples 97-99 (E97-E99) were prepared using an analogous method to that described for Example 96 (E96) from 3-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxymethyl)-benzoic acid (E95) and the appropriate amine indicated in the table.

Example	Amine	LC/MS ($M+H^+$)
1-[3-(3-Cyclopentyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxymethyl)-phenyl]-1-morpholin-4-yl-methanone (E97)	Morpholine	435
1-[3-(3-Cyclopentyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxymethyl)-phenyl]-1-(4-pyridin-4-yl-piperazin-1-yl)-methanone (E98)	1-Pyridin-4-yl-piperazine	511
1-[3-(3-Cyclopentyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxymethyl)-phenyl]-1-[4-(4-fluoro-phenyl)-piperazin-1-yl]-methanone (E99)	1-(4-Fluoro-phenyl)-piperazine	528

Example 100
6-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-nicotinonitrile (E100)



Sodium hydride (60% disp. in mineral oil, 60 mg, 1.5 mmol) was added to a stirred solution of 3-cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[d]azepin-7-ol (E3) (200 mg, 0.9 mmol) in dimethyl sulfoxide (10 ml). After 0.5 hours, 6-chloronicotinylnitrile (250 mg, 1.8 mmol) was added and the reaction mixture was heated to 120 °C for 6 hours. The reaction was allowed to cool and the crude mixture was applied to a SCX cartridge (Varian bond-elute, 10 g) and washed with methanol and then a mixture of .880 ammonia/methanol. The combined basic fractions were reduced in vacuo to afford the title compound (E100). MS (ES+) m/e 320 $[M+H]^+$.

Examples 101-120

Examples 101-120 (E101-E120) were prepared using an analogous method to that described for Example 100 (E100) from 3-cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[d]azepin-7-ol (E3) and the appropriate aromatic chloride indicated in the table:

Example	Chloride	LC/MS ($M+H^+$)
3-Cyclobutyl-7-(pyridin-2-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E101)	2-Chloro-pyridine	295
1-[6-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-pyridin-3-yl]-1-morpholin-4-yl-methanone (E102)	1-(6-Chloro-pyridin-3-yl)-1-morpholin-4-yl-methanone (D6)	408
1-[6-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-pyridin-3-yl]-1-pyrrolidin-1-l-methanone (E103)	1-(6-Chloro-pyridin-3-yl)-1-pyrrolidin-1-yl-methanone (D7)	392
6-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-nicotinamide (E104)	6-Chloro-nicotinamide (D8)	338
6-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-*N,N*-dimethyl-nicotinamide (E105)	6-Chloro-*N,N*-dimethyl-nicotinamide (D9)	366
6-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-*N*-ethyl-*N*-methyl-nicotinamide (E106)	6-Chloro-*N*-ethyl-*N*-methyl-nicotinamide (D10)	380
6-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-*N*-cyclopentyl-nicotinamide (E107)	6-Chloro-*N*-cyclopentyl-nicotinamide (D12)	406
1-[6-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-pyridin-3-yl]-1-piperidin-1-yl-methanone (E108)	1-(6-Chloro-pyridin-3-yl)-1-piperidin-1-yl-methanone (D13)	406
1-[2-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-pyridin-4-yl]-1-piperidin-1-yl-methanone (E109)	1-(2-Chloro-pyridin-4-yl)-1-piperidin-1-yl-methanone (D14)	406

1-[2-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-pyridin-4-yl]-1-pyrrolidin-1-yl-methanone (E110)	1-(2-Chloro-pyridin-4-yl)-1-pyrrolidin-1-yl-methanone (D15)	392
1-[2-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-pyridin-4-yl]-1-morpholin-4-yl-methanone (E111)	1-(2-Chloro-pyridin-4-yl)-1-morpholin-4-yl-methanone (D16)	408
1-[6-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-pyridin-2-yl]-1-piperidin-1-yl-methanone (E112)	1-(6-Chloro-pyridin-2-yl)-1-piperidin-1-yl-methanone (D17)	406
1-[6-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-pyridin-2-yl]-1-(1,1-dioxothiomorpholin-4-yl)-methanone (E113)	1-(6-Chloro-pyridin-2-yl)-1-(1,1-dioxothiomorpholin-4-yl)-methanone (D18)	466
1-[6-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-pyridin-2-yl]-1-pyrrolidin-1-yl-methanone (E114)	1-(6-Chloro-pyridin-2-yl)-1-pyrrolidin-1-yl-methanone (D19)	392
1-[6-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-pyridin-2-yl]-1-morpholin-4-yl-methanone (E115)	1-(6-Chloro-pyridin-2-yl)-1-morpholin-4-yl-methanone (D20)	408
1-[2-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-pyridin-3-yl]-1-morpholin-4-yl-methanone (E116)	1-(2-Chloro-pyridin-3-yl)-1-morpholin-4-yl-methanone (D21)	408
1-[2-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-pyridin-3-yl]-1-piperidin-1-yl-methanone (E117)	1-(2-Chloro-pyridin-3-yl)-1-piperidin-1-yl-methanone (D22)	406
3-Cyclobutyl-7-(pyrazin-2-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E118)	2-Chloro-pyrazine	296
3-Cyclobutyl-7-(pyrimidin-2-yloxy)-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E119)	2-Chloro-pyrimidine	296
7-(5-Bromo-pyrimidin-2-yloxy)-3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E120)	5-Bromo-2-chloro-pyrimidine	375

Example 121

6-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-*N*-methyl-nicotinamide (E121)



Sodium hydride (60% disp. in mineral oil, 60 mg, 1.5 mmol) was added to a stirred solution of 3-cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[d]azepin-7-ol (E3) (200 mg, 0.9 mmol) in dimethyl sulfoxide (10 ml). After 0.5 hours, 6-chloro-*N*-methyl-nicotinamide (D11) (400 mg, 2.5 mmol) was added and the reaction mixture was heated to 120 °C for 6 hours. The reaction was allowed to cool and the crude mixture was applied to a SCX cartridge (Varian bond-elute, 10 g) and washed with methanol and then a mixture of .880 ammonia/methanol. The combined basic fractions were reduced in vacuo to afford the title compound (E121). MS (ES+) m/e 352 $[M+H]^+$.

Example 122

5-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-pyrazine-2-carboxylic acid methyl ester (E122)



Sodium hydride (60% disp. in mineral oil, 332 mg, 8.3 mmol) was added to a stirred solution of 3-cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (E3) (1.64 g, 7.5 mmol) in dimethyl formamide (4 ml). After 0.5 hours, a solution of 5-chloro-pyrazine-2-carboxylic acid methyl ester (1.95 g, 11.3 mmol) in dimethyl formamide (8 ml) was added and the reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with dichloromethane and the organic layer was washed with water, brine and dried over magnesium sulfate. The organic layer was filtered, concentrated in vacuo and the resulting residue was purified by column chromatography (1:9:90 .880 ammonia:ethanol:dichloromethane) to afford the title compound (E122). MS (ES+) m/e 354 $[M+H]^+$.

Example 123

1-[5-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-pyrazin-2-yl]-1-morpholin-4-yl-methanone (E123)



Morpholine (0.17 ml, 2.0 mmol) was added to a stirred solution of 5-(3-cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-pyrazine-2-carbonyl chloride (D34) (394 mg, 1 mmol) and diethylaminomethyl polystyrene (1.88 g, 3.2 mmol/g, 6 mmol) in dichloromethane (10 ml). The resulting mixture was allowed to stir at room temperature for 24 hours and the filtered. The filtrate was concentrated in vacuo and the resulting crude residue was purified column chromatography (1:9:90 .880 ammonia:ethanol:dichloromethane) to afford the title compound (E123). MS (ES+) m/e 409 $[M+H]^+$.

Examples 124-127

Examples 124-127 (E124-E127) were prepared using an analogous method to that described for Example 123 from 5-(3-cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-pyrazine-2-carbonyl chloride (D34) and the appropriate amine indicated in the table:

Example	Amine	LC/MS ($M+H^+$)
5-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-pyrazine-2-carboxylic acid ethylmethyl amide (E124)	*N*-Ethylmethyl amine	381
5-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-pyrazine-2-carboxylic acid methyl amide (E125)	Methyl amine	353
1-[5-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-pyrazin-2-yl]-1-piperidin-4-yl-methanone (E126)	Piperidine	407
1-[5-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-pyrazin-2-yl]-1-pyrrolidin-4-yl-methanone (E127)	Pyrrolidine	393

Example 128

3-Cyclobutyl-7-phenoxy-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E128)



Sodium hydride (60% disp. in mineral oil, 96 mg, 2.4 mmol) was added to a stirred solution of 3-cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (E3) (435 mg, 2.0 mmol) and copper (I) bromide (402 mg, 2.8 mmol) in pyridine (10 ml) at 0 °C. After stirring for 0.5 hour at room temperature, iodobenzene (0.45 ml, 4.0 mmol) was added and the reaction mixture was heated to 135 °C for 24 hours. The reaction was allowed to cool, filtered and the filtrate was concentrated in vacuo. The crude residue was dissolved with ethyl acetate and washed with water and brine. The organic layer was dried over magnesium sulfate, filtered and concentrated in vacuo. Purification of the resulting residue by column chromatography (0.25:2.25:97.5 to 1:9:10 .880 ammonia:ethanol:dichloromethane) afforded the title compound (E128). MS (ES+) m/e 294 $[M+H]^+$.

Examples 129-138

Examples 129-138 (E129-E138) were prepared using an analogous method to that described for Example 128 (E128) from 3-cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (E3) and the appropriate aromatic chloride indicated in the table:

Example	Aromatic chloride	LC/MS ($M+H^+$)
1-[4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-phenyl]-1-morpholin-4-yl-methanone (E129)	1-(4-Chloro-phenyl)-1-morpholin-4-yl-methanone (D23)	407
4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-*N*-cyclopropylmethyl-benzamide (E130)	4-Chloro-N-cyclopropylmethyl-benzamide (D24)	391
1-[4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-phenyl]-1-pyrrolidin-1-yl-methanone (E131)	1-(4-Chloro-phenyl)-1-pyrrolidin-1-yl-methanone (D25)	391
N-Cyclobutyl-4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-benzamide (E132)	4-Chloro-N-cyclobutyl-benzamide (D26)	391
4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-*N,N*-diethyl-benzamide (E133)	4-Chloro-*N,N*-diethyl-benzamide (D27)	393
N-(2-Cyano-ethyl)-4-(3-cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-N-methyl-benzamide (E134)	4-Chloro-*N*-(2-cyano-ethyl)-*N*-methyl-benzamide (D28)	404
3-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-*N*-cyclopropylmethyl-benzamide (E135)	3-Chloro-N-cyclopropylmethyl-benzamide (D30)	391
1-[3-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-phenyl]-1-morpholin-4-yl-methanone (E136)	1-(3-Chloro-phenyl)-1-morpholin-4-yl-methanone (D29)	407
3-Cyclobutyl-7-[4-(morpholine-4-sulfonyl)-phenxoy]-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine (E137)	4-(4-Chloro-benzenesulfonyl)-morpholine (D31)	443
4-(3-Cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-N,N-diethyl-benzenesulfonamide (E138)	4-Chloro-*N,N*-diethyl-benzenesulfonamide (D32)	429

Example 139

7-Benzyloxy-3-cyclohexyl-2,3,4,5-tetrahydro-1*H*-benzo[d]azepine (E139)



Example 139 (E139) was prepared using the method described for Example 1, substituting cyclobutanone for cyclohexanone. MS (ES+) m/e 336 $[M+H]^+$.

All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

Biological Data

A membrane preparation containing histamine H3 receptors may be prepared in accordance with the following procedures:

(i) Generation of histamine H3 cell line

The histamine H3 cDNA was isolated from its holding vector, pCDNA3.1 TOPO (InVitrogen), by restriction digestion of plasmid DNA with the enzymes BamH1 and Not-1 and ligated into the inducible expression vector pGene (InVitrogen) digested with the same enzymes. The GeneSwitch™ system (a system where in transgene expression is switched off in the absence of an inducer and switched on in the presence of an inducer) was performed as described in US Patent nos: 5,364,791; 5,874,534; and 5,935,934. Ligated DNA was transformed into competent DH5α *E. coli* host bacterial cells and plated onto Luria Broth (LB) agar containing Zeocin™ (an antibiotic which allows the selection of cells expressing the *sh ble* gene which is present on pGene and pSwitch) at 50μg ml^{-1}. Colonies containing the re-ligated plasmid were identified by restriction analysis. DNA for transfection into mammalian cells was prepared from 250ml cultures of the host bacterium containing the pGeneH3 plasmid and isolated using a DNA preparation kit (Qiagen Midi-Prep) as per manufacturers guidelines (Qiagen).
CHO K1 cells previously transfected with the pSwitch regulatory plasmid (InVitrogen) were seeded at 2x10e6 cells per T75 flask in Complete Medium, containing Hams F12 (GIBCOBRL, Life Technologies) medium supplemented with 10% v/v dialysed foetal bovine serum, L-glutamine, and hygromycin (100μg ml^{-1}), 24 hours prior to use. Plasmid DNA was transfected into the cells using Lipofectamine plus according to the manufacturers guidelines (InVitrogen). 48 hours post transfection cells were placed into complete medium supplemented with 500μg ml^{-1} Zeocin™.
10-14 days post selection 10nM Mifepristone (InVitrogen), was added to the culture medium to induce the expression of the receptor. 18 hours post induction cells were detached from the flask using ethylenediamine tetra-acetic acid (EDTA; 1:5000; InVitrogen), following several washes with phosphate buffered saline pH 7.4 and resuspended in Sorting Medium containing Minimum Essential Medium (MEM), without phenol red, and supplemented with Earles salts and 3% Foetal Clone II (Hyclone).

Approximately 1x 10e7 cells were examined for receptor expression by staining with a rabbit polyclonal antibody, 4a, raised against the N-terminal domain of the histamine H3 receptor, incubated on ice for 60 minutes, followed by two washes in sorting medium. Receptor bound antibody was detected by incubation of the cells for 60 minutes on ice with a goat anti rabbit antibody, conjugated with Alexa 488 fluorescence marker (Molecular Probes). Following two further washes with Sorting Medium, cells were filtered through a 50μm Filcon™ (BD Biosciences) and then analysed on a FACS Vantage SE Flow Cytometer fitted with an Automatic Cell Deposition Unit. Control cells were non-induced cells treated in a similar manner. Positively stained cells were sorted as single cells into 96-well plates, containing Complete Medium containing 500μg ml^{-1} Zeocin™ and allowed to expand before reanalysis for receptor expression via antibody and ligand binding studies. One clone, 3H3, was selected for membrane preparation.

(ii) Membrane preparation from cultured cells

All steps of the protocol are carried out at 4°C and with pre-cooled reagents. The cell pellet is resuspended in 10 volumes of buffer A2 containing 50mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES) (pH 7.40) supplemented with 10e-4M leupeptin (acetyl-leucyl-leucyl-arginal; Sigma L2884), 25μg/ml bacitracin (Sigma B0125), 1mM ethylenediamine tetra-acetic acid (EDTA), 1mM phenylmethylsulfonyl fluoride (PMSF) and 2x10e-6M pepstain A (Sigma). The cells are then homogenised by 2 x 15 second bursts in a 1 litre glass Waring blender, followed by centrifugation at 500g for 20 minutes. The supernatant is then spun at 48,000g for 30 minutes. The pellet is resuspended in 4 volumes of buffer A2 by vortexing for 5 seconds, followed by homogenisation in a Dounce homogeniser (10-15 strokes). At this point the preparation is aliquoted into polypropylene tubes and stored at -70°C.

Compounds of the invention may be tested for *in vitro* biological activity in accordance with the following assays:

(I) Histamine H3 binding assay

For each compound being assayed, in a white walled clear bottom 96 well plate, is added:-

(a) 10μl of test compound (or 10μl of iodophenpropit (a known histamine H3 antagonist) at a final concentration of 10mM) diluted to the required concentration in 10% DMSO;

(b) 10μl ^{125}I 4-[3-(4-iodophenylmethoxy)propyl]-1H-imidazolium (iodoproxyfan) (Amersham; 1.85MBq/μl or 50μCi/ml; Specific Activity ~2000Ci/mmol) diluted to 200pM in assay buffer (50mM Tris(hydroxymethyl)aminomethane buffer (TRIS) pH 7.4, 0.5mM ethylenediamine tetra-acetic acid (EDTA)) to give 20pM final concentration; and

(c) 80μl bead/membrane mix prepared by suspending Scintillation Proximity Assay (SPA) bead type WGA-PVT at 100mg/ml in assay buffer followed by mixing with membrane (prepared in accordance with the methodology described above) and diluting

in assay buffer to give a final volume of 80µl which contains 7.5µg protein and 0.25mg bead per well – mixture was pre-mixed at room temperature for 60 minutes on a roller. The plate is shaken for 5 minutes and then allowed to stand at room temperature for 3-4 hours prior to reading in a Wallac Microbeta counter on a 1 minute normalised tritium count protocol. Data was analysed using a 4-parameter logistic equation.

(II) Histamine H3 functional antagonist assay

For each compound being assayed, in a white walled clear bottom 96 well plate, is added:-

(a) 10µl of test compound (or 10µl of guanosine 5'- triphosphate (GTP) (Sigma) as non-specific binding control) diluted to required concentration in assay buffer (20mM N-2-Hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES) + 100mM NaCl + 10mM $MgCl_2$, pH7.4 NaOH);

(b) 60µl bead/membrane/GDP mix prepared by suspending wheat germ agglutinin-polyvinyltoluene (WGA-PVT) scintillation proximity assay (SPA) beads at 100mg/ml in assay buffer followed by mixing with membrane (prepared in accordance with the methodology described above) and diluting in assay buffer to give a final volume of 60µl which contains 10µg protein and 0.5mg bead per well – mixture is pre-mixed at 4°C for 30 minutes on a roller and just prior to addition to the plate, 10µM final concentration of guanosine 5' diphosphate (GDP) (Sigma; diluted in assay buffer) is added;

The plate is incubated at room temperature to equilibrate antagonist with receptor/beads by shaking for 30 minutes followed by addition of:

(c) 10µl histamine (Tocris) at a final concentration of 0.3µM; and

(d) 20µl guanosine 5' [γ35-S] thiotriphosphate, triethylamine salt (Amersham; radioactivity concentration = 37kBq/µl or 1mCi/ml; Specific Activity 1160Ci/mmol) diluted to 1.9nM in assay buffer to give 0.38nM final.

The plate is then incubated on a shaker at room temperature for 30 minutes followed by centrifugation for 5 minutes at 1500 rpm. The plate is read between 3 and 6 hours after completion of centrifuge run in a Wallac Microbeta counter on a 1 minute normalised tritium count protocol. Data is analysed using a 4-parameter logistic equation. Basal activity used as minimum i.e. histamine not added to well.

Results

The compounds of Examples E1-3, E5-139 were tested in the histamine H3 functional antagonist assay and exhibited antagonism in the following range: 6.5-10.5 pK_b. More particularly, the compounds of Examples 1, 52 and 121 exhibited antagonism in the following range: 9.0-10.5 pK_b.

CLAIMS:

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:



(I)

wherein:
R^1 represents -C_{3-7} cycloalkyl optionally substituted by C_{1-3} alkyl;
R^2 represents hydrogen, -C_{1-6} alkyl, -X-C_{3-8} cycloalkyl, -X-aryl, -X-heterocyclyl, -X-heteroaryl, -X-C_{3-8} cycloalkyl-Y-C_{3-8} cycloalkyl, -X-C_{3-8} cycloalkyl-Y-aryl, -X-C_{3-8} cycloalkyl-Y-heteroaryl, -X-C_{3-8} cycloalkyl-Y-heterocyclyl, -X-aryl-Y-C_{3-8} cycloalkyl, -X-aryl-Y-aryl, -X-aryl-Y-heteroaryl, -X-aryl-Y-heterocyclyl, -X-heteroaryl-Y-C_{3-8} cycloalkyl, -X-heteroaryl-Y-aryl, -X-heteroaryl-Y-heteroaryl, -X-heteroaryl-Y-heterocyclyl, -X-heterocyclyl-Y-C_{3-8} cycloalkyl, -X-heterocyclyl-Y-aryl, -X-heterocyclyl-Y-heteroaryl, -X-heterocyclyl-Y-heterocyclyl;
X represents a bond or C_{1-6} alkyl;
Y represents a bond, C_{1-6} alkyl, CO, COC_{2-6} alkenyl, O or SO_2;
R^3 represents halogen, C_{1-6} alkyl, C_{1-6} alkoxy, cyano, amino or trifluoromethyl;
n is 0, 1 or 2;
wherein said C_{1-6} alkyl, C_{3-8} cycloalkyl, aryl, heteroaryl and heterocyclyl groups of R^2 may be optionally substituted by one or more substituents (eg. 1, 2 or 3) which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, oxo, trifluoromethyl, trifluoromethoxy, fluoromethoxy, difluoromethoxy, C_{1-6} alkyl, pentafluoroethyl, C_{1-6} alkoxy, arylC_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} alkoxyC_{1-6} alkyl, C_{3-7} cycloalkylC_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkoxycarbonyl, C_{1-6} alkylsulfonyl, C_{1-6} alkylsulfinyl, C_{1-6} alkylsulfonyloxy, C_{1-6} alkylsulfonylC_{1-6} alkyl, sulfonyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC_{1-6} alkyl, aryloxy, C_{1-6} alkylsulfonamido, C_{1-6} alkylamino, C_{1-6} alkylamido, -R^4, -CO_2R^4, -COR^4, C_{1-6} alkylsulfonamidoC_{1-6} alkyl, C_{1-6} alkylamidoC_{1-6} alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC_{1-6} alkyl, arylcarboxamidoC_{1-6} alkyl, aroyl, aroylC_{1-6} alkyl, arylC_{1-6} alkanoyl, or a group -NR^5R^6, –C_{1-6} alkyl-NR^5R^6, –C_{3-8} cycloalkyl-NR^5R^6, -$CONR^5R^6$, -$NCOR^5R^6$, -$NSO_2R^5R^6$, -$OCONR^5R^6$, -$NCO_2R^5R^6$, -$NCONR^5R^6$ or -$SO_2NR^5R^6$ (wherein R^4, R^5 and R^6 independently represent hydrogen, C_{1-6} alkyl, -C_{3-8} cycloalkyl, -C_{1-6} alkyl-C_{3-8} cycloalkyl, aryl, heterocyclyl or heteroaryl or -NR^5R^6 may represent a heterocyclyl group, wherein said R^4, R^5 and R^6 groups may be optionally substituted by one or more substituents (eg. 1, 2 or 3) which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, cyano, amino, oxo or trifluoromethyl);
or solvates thereof.

2. A compound according to claim 1 which is a compound of formula E1-E139 or a pharmaceutically acceptable salt thereof.

3. A compound according to claim 1 or claim 2 for use in therapy.

4. A compound according to claim 1 or claim 2 for use in the treatment of Alzheimer's disease.

5. A pharmaceutical composition which comprises a compound according to claim 1 or claim 2 and a pharmaceutically acceptable carrier or excipient.